Adult Clinical Trials - Non-immunologic

Clinical Research

ACTR-66 - A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent IDH1 mutant, low-grade glioma: Updated results

Oral Abstract Speaker(s)

• IM

  Ingo Mellinghoff

  Memorial Sloan Kettering Cancer Center

Author(s)

• 

  Timothy Cloughesy

  Professor
  University of California Los Angeles
• 

  Patrick Wen

  Director, Center For Neuro-Oncology
  Dana-Farber Cancer Institute
• 

  Jennie Taylor

  Assistant Professor
  Division of Neuro-Oncology UCSF
• EM

  Elizabeth Maher

  University of Texas Southwestern Medical Center
• IA

  Isabel Arrillaga-Romany

  Attending Neuro-Oncologist
  Massachusetts General Hospital
• 

  Katherine Peters

  Associate Professor
  Duke University Medical Center
• 

  Changho Choi

  Professor
  University of Texas Southwestern Medical Center
• 

  Benjamin Ellingson

  Professor
  University of California Los Angeles
• AL

  Alexander Lin

  Dana-Farber Cancer Institute, Harvard Medical School
• ST

  Sunitha Thakur

  Memorial Sloan Kettering Cancer Center
• BN

  Brandon Nicolay

  Agios Pharmaceuticals, Inc.
• ML

  Min Lu

  Agios Pharmaceuticals, Inc.
• KL

  Kha Le

  Agios Pharmaceuticals, Inc.
• FY

  Feng Yin

  Agios Pharmaceuticals, Inc.
• FT

  Feng Tai

  Agios Pharmaceuticals, Inc.
• SS

  Steven Schoenfeld

  Agios Pharmaceuticals, Inc.
• SP

  Shuchi S Pandya

  Agios Pharmaceuticals, Inc.
• IH

  Islam Hassan

  Agios Pharmaceuticals, Inc.
• LS

  Lori Steelman

  Agios Pharmaceuticals, Inc.
• 

  Jennifer Clarke

  University of California, San Francisco